Safety and Efficacy of LCL161 in Patients With Solid Tumors

Phase 1 Completed 71 enrolled Novartis Pharmaceuticals

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The study will evaluate the safety of increasing doses of oral LCL161 in patients with solid tumors. It is primarily designed to evaluate the side effects and find the maximum tolerated dose of LCL161.

Timeline

Start: 2008-11
Primary completion: 2011-01
Completion: 2011-01

Publications

Infante JR, Dees EC, Olszanski AJ, Dhuria SV, Sen S, Cameron S, Cohen RB. Phase I dose-escalation study of LCL161, an oral inhibitor of apoptosis proteins inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2014 Oct 1;32(28):3103-10. doi: 10.1200/JCO.2013.52.3993. Epub 2014 Aug 11.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LCL161	Small molecule	10 mg	Oral
Subject	LCL161	Small molecule	1800 mg	Oral
Subject	LCL161	Small molecule	3000 mg	Oral

Safety and Efficacy of LCL161 in Patients With Solid Tumors

Summary

Timeline

Publications

Drugs

Indications